Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CM-101 in Healthy Male Subjects
NCT06025851Phase 1Completed
- Sponsor
- Chemomab Therapeutics
- Start
- Jul 2017
- Primary completion
- Feb 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC) and systemic sclerosis (SSc) comparing CM-101 with Placebo (2 arms). Primary endpoints: Incidence and characteristics of adverse events at 10 weeks, Maximum CM-101 plasma concentration at 10 weeks and 4 more. Started Jul 2017; status: completed.
02
Drugs
nebokitug
03
Conditions
Nonalcoholic steatohepatitis (NASH)Primary Sclerosing Cholangitis (PSC)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06025851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06025851.